AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00157573
Drug: GM-CSF, sargramostim
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GM-CSF subcutaneous injection
Trial: NCT04344782
Drug: Bevacizumab Injection
RxNorm normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment includes the administration on day 1 (D1) of an infusion of Bevacizumab 7.5 mg / kg in 100 ml saline for all patients weighing 100 kg or more. In control arm, patient receives standard care.
Trial: NCT00312754
Drug: Atazanavir
RxNorm normalized name: Atazanavir
DrugBank: Atazanavir (DB01072)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00828581
Drug: lorcaserin
RxNorm normalized name: Lorcaserin
DrugBank: Lorcaserin (DB04871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01288417
Drug: boceprevir
RxNorm normalized name: Boceprevir
DrugBank: Boceprevir (DB08873)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 days of boceprevir 800mg TID
Trial: NCT01288417
Drug: raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: raltegravir 400mg single dose
Trial: NCT00397293
Drug: AT-101
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of AT-101 (by mouth) on days 1-5 of each 21 day cycle with topotecan 1.25 mg/m2, IV (in the vein) on days 1-5 of each 21 day cycle for approx. 4 cycles or until progression or unacceptable toxicity develops.
Trial: NCT00397293
Drug: topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg of AT-101 (by mouth) on days 1-5 of each 21 day cycle with topotecan 1.25 mg/m2, IV (in the vein) on days 1-5 of each 21 day cycle for approx. 4 cycles or until progression or unacceptable toxicity develops.
Trial: NCT03813394
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: -Pembrolizumab in Solution for Injection
Trial: NCT03813394
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * Bevacizumab in Concentrate for Solution~* Bevacizumab in Concentrate for Solution
Trial: NCT03598673
Drug: The Efficacy and Tolerability of Nebivolol in Nigerians
RxNorm normalized name: valsartan and nebivolol
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To determine the effect of Nevibolol on office blood pressure of Blacks residing in Nigeria
Trial: NCT02426294
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02426294
Drug: Glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01261429
Drug: Tasigna
RxNorm normalized name: Tasigna
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study drug is nilotinib (Tasigna®). All patients will be administered with nilotinib 400 mg twice a day for one year. The patient will begin the treatment the day of inclusion.~The prescribed dose should be swallowed whole with a glass of water. Doses of 400 mg should be administered twice daily approximately 12 hours apart. Patients should not eat within two hours before and one hour after taking nilotinib and need to avoid foods such as grapefruit juice which may inhibit CYP3A4 enzymes.
Trial: NCT01787344
Drug: Botulinum Toxin Type A(Botox®)
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Single administration, 4units/kg body weight dose in patients with hemiplegia, 6units/kg body weight dose in patients with diplegia, Maximum dosage 200units
Trial: NCT01787344
Drug: Botulinum toxin type A(Botulax®)
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Single administration, 4units/kg body weight dose in patients with hemiplegia,6units/kg body weight dose in patients with diplegia, Maximum dosage 200units
Trial: NCT00321087
Drug: T2000
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose escalation from 600 to 1000 mg
Trial: NCT00321087
Drug: T2000
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo followed by T2000 dose escalation from 600 to 1000 mg
Trial: NCT00321087
Drug: T2000
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo followed by dose escalation from 600 to 1000
Trial: NCT01984931
Drug: Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)
RxNorm normalized name: trimebutine
DrugBank: Trimebutine (DB09089)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)is a noncompetitive spasmolytic agent. It possesses moderate opiate receptor affinity and has marked anti-serotonin activity especially on'M' receptors. A single dose of NEWBUTIN SR 300 mg Tab orally will be given one hour prior to the said operation time and another 300 mg orally as soon as the patient wakes post operatively.
Trial: NCT01984931
Drug: Metoclopramide hydrochloride monohydrate
RxNorm normalized name: Metoclopramide Hydrochloride
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01615757
Drug: Ara-c
RxNorm normalized name: Ara-C
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 3 gm/m2 /dose
Trial: NCT01615757
Drug: Ara-c
RxNorm normalized name: Ara-C
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 2 gm/m2 /dose
Trial: NCT01895829
Drug: Ferumoxytol
RxNorm normalized name: Ferumoxytol
DrugBank: Ferumoxytol (DB06215)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein.
Trial: NCT01733212
Drug: Ginger
RxNorm normalized name: Ginger
DrugBank: Ginger (DB10344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger is an herb. The rhizome (underground stem) is used as a spice and also as a medicine. It can be used fresh, dried and powdered, or as a juice or oil. Two capsules (1g each) of dry powdered ginger are given, one capsule a half-hour before induction of anesthesia and the second 2h after surgery.
Trial: NCT03253562
Drug: Metformin Pill
RxNorm normalized name: metformin Pill
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: a biguanide used as an insulin sensitizer for patients suffering from type 2 diabetes mellitus
Trial: NCT03253562
Drug: Vildagliptin 50 mg
RxNorm normalized name: vildagliptin 50 MG
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Dpp4i antihyperglycemic drug used for treatment of type 2 diabetes mellitus
Trial: NCT00204555
Drug: Imiquimod
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03452475
Drug: Arterolane-piperaquine
RxNorm normalized name: Piperazine
DrugBank: Piperaquine (DB13941)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Arterolane maleate-piperaquine phosphate tablets (37.5 mg/187.5 mg)
Trial: NCT03452475
Drug: Arterolane-piperaquine+mefloquine
RxNorm normalized name: arterolane and piperaquine
DrugBank: Mefloquine (DB00358)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arterolane maleate-piperaquine phosphate tablets (37.5 mg/187.5 mg) Mefloquine tablets (250 mg)
Trial: NCT01847131
Drug: oxymetazoline
RxNorm normalized name: Oxymetazoline
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.05% Oxymetazoline nasal sprays were commercially available.
Trial: NCT01445548
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00853216
Drug: Oxycodone hydrochloride tablet 30 mg
RxNorm normalized name: oxycodone hydrochloride Oral Tablet
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone hydrochloride tablet 30 mg, single dose fasting
Trial: NCT00002671
Drug: aminocamptothecin
RxNorm normalized name: Aminocamptothecin
DrugBank: 9-aminocamptothecin (DB12515)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04224688
Drug: Rozanolixizumab
RxNorm normalized name: Rozanolixizumab
DrugBank: Rozanolixizumab (DB14919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants receive rozanolixizumab by subcutaneous infusion at pre-specified time points.
Trial: NCT00324298
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00324298
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00382642
Drug: Ondansetron + Cognitive Behavioral Therapy
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 13 week outpatient trial
Trial: NCT02228616
Drug: Prucalopride
RxNorm normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: During the 12-week treatment phase of the study, the daily dose of 1 tablet of 2-mg prucalopride will be administrated orally before breakfast.
Trial: NCT02228616
Drug: Polyethylene glycol (PEG)
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized dose of PEG will be administrated for 13 weeks (1 week run-in+12 weeks intervention).
Trial: NCT02228616
Drug: Lactulose
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Optimized dose of Lactulose will be administrated for 13 weeks (1 week run-in+12 weeks intervention).
Trial: NCT00934648
Drug: rituximab [MabThera/Rituxan]
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1000mg iv on days 1 and 15
Trial: NCT02367807
Drug: Emtricitabine and tenofovir disoproxil fumarate
RxNorm normalized name: Emtricitabine and Tenofovir Disoproxil Fumarate Tablets
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This study will enroll 50 subjects who are offered TDF/FTC for 48 weeks as part of a combined biomedical/behavioral intervention offered in a community-based setting serving high-risk youth in an urban setting.
Trial: NCT01482390
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive a total daily dose of 1000 milligrams (mg) (for participants weighing less than \[\<\] 75 kg) or 1200 mg (for participants weighing greater than or equal to \[\>=\] 75 kg) orally for 24 or 48 weeks.
Trial: NCT01482390
Drug: Mericitabine
RxNorm normalized name: Mericitabine
DrugBank: Mericitabine (DB12045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive mericitabine 1000 mg orally twice daily.
Trial: NCT01482390
Drug: Peginterferon Alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 180 micrograms (mcg) subcutaneous injection once weekly.
Trial: NCT01482390
Drug: Telaprevir
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive telaprevir 750 mg orally three times daily.
Trial: NCT01579812
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients receiving primary surgical debulking followed by adjuvant chemotherapy will initiate metformin prior to primary surgery. Following surgery patients will be initiated on metformin prior to the initiation of chemotherapy.~Patients treated with neoadjuvant chemotherapy will be initiated on metformin prior to the initiation of chemotherapy. Following surgery patients will be initiated on metformin prior to the re-initiation of chemotherapy.
Trial: NCT01071083
Drug: natalizumab
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300 mg intravenous every 4 weeks
Trial: NCT01071083
Drug: interferon beta 1-a
RxNorm normalized name: Interferon beta 1-a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 ug intramuscular once per week
Trial: NCT01071083
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000 mg intravenous every 4 weeks
Trial: NCT01071083
Drug: glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg subcutaneous once daily
Trial: NCT01695876
Drug: AMG 357
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration available in varying dose strength.
Trial: NCT03972709
Drug: Galegenimab
RxNorm normalized name: Galegenimab
DrugBank: Galegenimab (DB18860)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal (ITV) injections of galegenimab
Trial: NCT03972709
Drug: Sham Control
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
DrugBank: Bean (DB14709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham control
Trial: NCT03406611
Drug: Pegtibatinase
RxNorm normalized name: Pegtibatinase
DrugBank: Pegtibatinase (DB17677)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegtibatinase sterile solution for subcutaneous injection
Trial: NCT01970904
Drug: Alisporivir
RxNorm normalized name: Alisporivir
DrugBank: Alisporivir (DB12139)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisporivir 100 mg or 200 mg soft gel capsules (SGC) in blister packs for oral administration
Trial: NCT01970904
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin tablets of various strengths for oral administration
Trial: NCT01970904
Drug: Peg-IFNα2a
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peg-IFNα2a solution for subcutaneous injection
Trial: NCT00005862
Drug: semaxanib
RxNorm normalized name: Semaxanib
DrugBank: Semaxanib (DB06436)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04652414
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 50mg will be administered enterally for 7 days.
Trial: NCT01319331
Drug: Alpha 1-Antitrypsin (AAT, Aralast NP)
RxNorm normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible subjects will be treated once a week for 8 weeks (8 total treatments).
Trial: NCT01743001
Drug: Macitentan 10 mg
RxNorm normalized name: macitentan 10 MG
DrugBank: Macitentan (DB08932)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Macitentan 10 mg oral tablet once daily
Trial: NCT02162407
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given as intravenous infusion (i.v.) over a period of 8 hours during euglycaemic clamp
Trial: NCT02470637
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:solution for injection~Route of administration: subcutaneous
Trial: NCT04221204
Drug: Highly selective FGFR1-3 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects in each cohort will receive a single oral dose of 3D185, followed by a 7-day washout period (i.e. single-dose PK study period). Then, subjects will receive consecutive daily doses (Once daily \[QD\], 28 days/cycle) until disease progression, death, unacceptable toxicity, or withdraw of informed consent, whichever comes first. The dose limiting toxicity (DLT) evaluation period includes the single-dose PK study period and the first treatment cycle (within 35 days after the first dose). The enrolled subjects will be sequentially assigned to the planned dose cohorts according to the protocol and receive 3D185 treatment to observe the occurrence of DLT.
Trial: NCT01291069
Drug: Tadalafil Citrate
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If allocated to the treatment arm, the patient will be given tadalfil citrate, 0.8-1 mg/kg/day in 1 daily dose. Maximum dose 40 mg. All patients will receive either study drug or placebo for a total of 20 days.
Trial: NCT00879008
Drug: Moxifloxacin (Avelox, BAY12-8039)
RxNorm normalized name: moxifloxacin Injection [Avelox]
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients from the normal praxis routine, treated with Moxifloxacin according to the local product information
Trial: NCT01291069
Drug: Sugar pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If allocated to the placebo arm, the child will be given a similar appearing medication; the placebo will be a mixture of Ora-Sweet® and Ora-Plus® in a 1:1 ratio. All patients will receive drug for 20 days
Trial: NCT04964193
Drug: Elzsa film-coated tablet
RxNorm normalized name: BENZALKONIUM CHLORIDE 1 g in 59 g TOPICAL GEL [Grape Scented Hand Sanitizer Anna Elsa 2]
DrugBank: Grape (DB10533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered with 240 mL of water
Trial: NCT04964193
Drug: Diane-35 Sugar-coated tablet
RxNorm normalized name: tiopronin
DrugBank: Tiopronin (DB06823)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered with 240 mL of water
Trial: NCT02247648
Drug: tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients from tramadol group received tramadol 100 mg day one, 100 mg day 2, and 200 mg day 3
Trial: NCT00195208
Drug: Pantoprazole for approximately 9 weeks
RxNorm normalized name: Pantoprazole Sodium for Injection
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02836509
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes.
Trial: NCT03593473
Drug: Intranasal Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Six intranasal sprays of oxytocin. Each insufflation delivers 4 IUs of oxytocin for a total oxytocin dosage of 24 IUs.
Trial: NCT02158364
Drug: Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
RxNorm normalized name: Measles virus vaccine live attenuated
DrugBank: Measles virus vaccine live attenuated (DB10315)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
Trial: NCT03027284
Drug: Merestinib
RxNorm normalized name: Merestinib
DrugBank: Merestinib (DB12381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03027284
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT03027284
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered IV
Trial: NCT00128323
Drug: Gentian violet 1% solution
DrugBank: Gentian violet cation (DB00406)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04234204
Drug: Fezolinetant
RxNorm normalized name: Fezolinetant
DrugBank: Fezolinetant (DB15669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00128323
Drug: Nystatin solution
RxNorm normalized name: Nystatin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02863718
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bruton's tyrosine kinase Inhibitor Ibrutinib 420mg daily
Trial: NCT00402779
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg by mouth daily
Trial: NCT03003728
Drug: Elotuzumab
RxNorm normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Elotuzumab 10 mg/kg via intravenous infusion on days -16, -3, 12, and 26
Trial: NCT03003728
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan 200 mg/m2 Ivia intravenous infusion on day -3
Trial: NCT03940976
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib is orally administered at 40mg Qd of each 28 day cycle.
Trial: NCT00816023
Drug: ecallantide
RxNorm normalized name: Ecallantide
DrugBank: Ecallantide (DB05311)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: infusion administered IV over the duration of the surgical procedure
Trial: NCT03003728
Drug: ALT-803
RxNorm normalized name: ALT-803 COMPONENT IL-15R.ALPHA.SU/FC FUSION PROTEIN
DrugBank: Inbakicept (DB16479)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALT-803 (Interleukin-15 superagonist) 10 ug/kg via subcutaneous injection on days 1, 8, 15, and 22
Trial: NCT01143805
Drug: Tasocitinib 10 mg oral tablet
RxNorm normalized name: Tasocitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment A: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of an oral tablet